Latest news with #SLEEP
Time Out
2 days ago
- Entertainment
- Time Out
Alexandra Palace is hosting a massive sleepover soundtracked by Max Richter
London's arts institutions love a good sleepover. You can already get 40 winks at the Natural History Museum' Dino Snores nights, the Science Museum's Astronights and the British Museum's sleepovers, and now another beloved London arts venue is hosting a truly special, limited-edition overnight experience this September in collaboration with British-German composer Max Richter in celebration of the tenth anniversary of his opus, SLEEP. Comprising 204 individual tracks, SLEEP is an epic, 8 hour and 30 minute-long lullaby created for listeners to fall asleep to, and has previously been performed live at overnight events in a bunch of iconic global settings, including Sydney Opera House, the Philharmonie de Paris and The Great Wall of China. The events – and the mammoth task of preparing for such lengthy performances – were also captured in a documentary of the same name, directed by Richter's creative partner Yulia Mahr. And now it's the turn of Alexandra Palace to host more of his truly special all-nighters. The north London music venue will be hosting two performances of SLEEP this September, marking the first time the piece has been performed in London since 2017. The concerts will start at 10pm and finish at around 6am as the sun rises, and audiences will be provided with beds and bedding, as well as being served a light breakfast at the end of the night. Fancy bunkering down in the Grade II-listed Great Hall for the night? Tickets for the event are on sale now via the Alexandra Palace website, with prices starting at £249.75 (steep for a concert, yes, but not unreasonable for a one-night stay in one of London's fancier hotels, which is how we prefer to think of the experience!)
Business Wire
11-06-2025
- Business
- Business Wire
Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the presentation of preclinical pharmacological effect data for BP1.15205, an investigational, highly potent, and potentially best-in-class orexin 2 receptor (OX2R) agonist, which demonstrated significant wake-promoting and cataplexy-suppressing effects in a standard transgenic mouse model of narcolepsy type 1. The data will be presented at the 39 th Annual Meeting of the Associated Professional Sleep Societies (APSS) 'SLEEP' on Wednesday, June 11, 2025, at 10:00 AM PDT in Seattle. 'We are encouraged by the robust preclinical data being presented at SLEEP, highlighting BP1.15205 as a potentially best-in-class OX2R agonist,' said Kumar Budur, MD, MS, Chief Medical and Scientific Officer at Harmony Biosciences. 'BP1.15205 is a new and unique chemical scaffold optimized for high potency that demonstrated statistically significant wake-promoting effects at very low doses administered orally in the standard transgenic mouse model. These findings are supportive of dosing flexibility to potentially treat all three central disorders of hypersomnolence at low doses, which could offer an optimized benefit / risk profile. The 3-month GLP toxicity study in two species revealed no concerning adverse events and supports a favorable safety and tolerability profile.' Orexin receptor functional studies showed that BP1.15205 is a highly potent, selective OX2R receptor agonist with no off-target effects expected and a >600-fold selectivity over human OX1R. BP1.15205 is orally bioavailable and has the potential for once-daily dosing. Absorption, distribution, metabolism, and excretion (ADME) properties and preliminary toxicology studies showed that BP1.15205 is a differentiated OX2R agonist drug candidate. In the GLP toxicity study, no adverse events or biochemical changes were observed following a 3-month treatment period at doses up to 300 mg/kg/day, pending histopathology data. An Investigational Medicinal Product Dossier (IMPD) application with the European Medicines Agency (EMA) is being completed for BP1.15205. A first-in-human study is planned to begin in 2H 2025 with topline data anticipated in 2026. Additionally, an Investigational New Drug (IND) application for BP1.15205 will be filed with the U.S. Food and Drug Administration (FDA). 'We are very excited to advance our potentially best-in-class OX2R program and support the strategic expansion of our sleep-wake franchise. We are dedicated to investigating this potential new solution further with the hope of bringing a novel treatment to market that can help even more people with narcolepsy and other central disorders of hypersomnolence,' Budur added. The poster entitled, 'BP1.15205, a Novel Orexin-2 Receptor Agonist, Demonstrates Pharmacological Effects in a Mouse Model of Narcolepsy,' will be presented at P-38; Poster Board Number 1; on June 11, 2025, at 10:00 AM PDT. KEY FINDINGS FROM THE STUDIES INCLUDE: In Vitro Orexin Receptor Functional Studies: BP1.15205 is a highly potent agonist at OX2R receptors: EC 50 = 0.015 nM. BP1.15205 is highly selective for human OX2R receptors: >600-fold selectivity over human OX1R receptors. Minimal interspecies difference in agonist functional properties was observed between human and mouse orexin-2 receptors. In Vivo Pharmacology Studies: Single oral dose administration of BP1.15205 in transgenic mice at the beginning of the 12-hour dark period of a 24-hour light/dark cycle produced significant and dose-dependent increases in total wakefulness time and sleep latency at every dose tested beginning at 0.03 and 0.1 mg/kg, respectfully, as compared to vehicle-treated animals. Significant and dose-dependent decreases in the total number and duration of cataplexy-like episodes were measured following single dose, oral administration of BP1.15205 beginning at 1mg/kg, as compared to vehicle. About Narcolepsy Narcolepsy is a rare, chronic, debilitating neurological disease of sleep-wake state instability that impacts approximately 170,000 Americans and is primarily characterized by excessive daytime sleepiness (EDS) and cataplexy – its two cardinal symptoms – along with other manifestations of REM sleep dysregulation (hallucinations and sleep paralysis), which intrude into wakefulness. EDS is the inability to stay awake and alert during the day and is the symptom that is present in all people living with narcolepsy. In most patients, narcolepsy is caused by the loss of hypocretin/orexin, a neuropeptide in the brain that supports sleep-wake state stability. This disease affects men and women equally, with typical symptom onset in adolescence or young adulthood; however, it can take up to a decade to be properly diagnosed. About Harmony Biosciences Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa., we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding our full year 2025 net product revenue, expectations for the growth and value of WAKIX, plans to submit an sNDA for pitolisant in idiopathic hypersomnia; our future results of operations and financial position, business strategy, products, prospective products, product approvals, the plans and objectives of management for future operations and future results of anticipated products. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our commercialization efforts and strategy for WAKIX; the rate and degree of market acceptance and clinical utility of pitolisant in additional indications, if approved, and any other product candidates we may develop or acquire, if approved, including ZYN002 and EPX-100; our research and development plans, including our plans to explore the therapeutic potential of pitolisant in additional indications; our ongoing and planned clinical trials; our ability to expand the scope of our license agreements with Bioprojet Société Civile de Recherche ('Bioprojet'); the availability of favorable insurance coverage and reimbursement for WAKIX; the timing of, and our ability to obtain, regulatory approvals for pitolisant for other indications as well as any other product candidates; our estimates regarding expenses, future revenue, capital requirements and additional financing needs; our ability to identify, acquire and integrate additional products or product candidates with significant commercial potential that are consistent with our commercial objectives; our commercialization, marketing and manufacturing capabilities and strategy; significant competition in our industry; our intellectual property position; loss or retirement of key members of management; failure to successfully execute our growth strategy, including any delays in our planned future growth; our failure to maintain effective internal controls; the impact of government laws and regulations; volatility and fluctuations in the price of our common stock; the significant costs and required management time as a result of operating as a public company; the fact that the price of Harmony's common stock may be volatile and fluctuate substantially; statements related to our intended share repurchases and repurchase timeframe; and macroeconomic effects and changes in market conditions, including the impact of tariffs, inflation and the risk of recession. These and other important factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on February 25, 2025, and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
Yahoo
05-06-2025
- Health
- Yahoo
SleepScore Study on Rest® Evercool® Collection to be Presented at SLEEP 2025 Conference and Published as an Abstract in SLEEP Journal
Study Highlights Positive Impact of Evercool Cooling Bedding on Perceived Sleep for Hot Sleepers NEWARK, Del., June 5, 2025 /PRNewswire/ -- Rest® and SleepScore Labs are proud to announce that the findings from its recent independent study evaluating the impact of the Rest® Evercool® Cooling Collection—including pillowcases, fitted sheets, and comforters— will be published as an abstract in SLEEP, a leading peer-reviewed journal in sleep and circadian science. In addition, the research team will present the study as a scientific poster at the upcoming SLEEP 2025 Conference, taking place June 8–11, a premier forum for sleep science and medicine. SleepScore Labs research analyzed approximately 1,000 nights of sleep among women aged 40–60 who reported sleeping hot, experiencing night sweats, or suffering from hot flashes. Results showed significant perceived improvements in sleep comfort, temperature regulation, and overall sleep quality when using Rest's Evercool® products compared to their original bedding. "Seeing our Evercool Collection independently validated by leading sleep researchers—and recognized by the scientific community through SLEEP and the SLEEP conference—is an incredible honor," said Andy Nguyen, CEO and Co-Founder of Rest®. "At Rest, our mission has always been to create products that make a real difference in how people sleep and feel, and we're proud to be part of the broader conversation about how innovation in bedding can support better, more restorative rest." Key Highlights of the Findings Include: Cooling Effect: 97% of participants reported that Rest's bedding felt cool, compared to only 16% who felt their original bedding was cool. Comfort: 100% of participants reported that Rest's bedding felt comfortable, whereas only 50% felt their original bedding was comfortable. Perceived Sleep Quality: Participants noted a significant increase in their perception of overall sleep quality (+74%). Ease of Falling Asleep: Participants found it easier to fall asleep (+91%) and were better able to fall asleep in their preferred amount of time (+80%). Reduced Night Sweats: Participants felt the intensity of night sweats was reduced (-61%). Better Sleep Satisfaction: Participants felt more satisfied with their sleep (+80%) and experienced this satisfaction more days per week (+118%). "By presenting this study as a scientific poster at the SLEEP 2025 conference, to be followed by its publication as an abstract, we're reinforcing our commitment to spotlighting consumer products that show promising potential to support better sleep," said Dr. Sharon Danoff-Burg, Senior Principal Research Scientist at SleepScore Labs. "We're proud to help bring solutions such as Rest's Evercool® collection into the conversation with the broader sleep community." To learn more about the study, visit . About SleepScore Labs SleepScore Labs is changing the world by empowering businesses to solve the world's sleep problems at scale by driving sleep improvement powered by science and world-leading data and technology. SleepScore Labs was founded by a team of sleep experts from companies, institutions, and organizations such as ResMed, Apple, Philips, and Harvard. After building and studying a proprietary dataset with more than 600 million hours of sleep & associated parameters, SleepScore Labs offers a suite of proven B2B2C services to help companies improve their health and wellness outcomes. To learn more, visit About Rest®Rest® is a sleep brand redefining the path to personalized comfort—prioritizing well-being through innovation in form, function, and cooling technology. Known for its Evercool® collection, Rest® offers a range of science-backed products all designed to support temperature regulation and all-night comfort. Many of Rest's products are eligible for purchase using Flexible Spending Accounts (FSA) and Health Savings Accounts (HSA). The brand has received widespread recognition, including Good Housekeeping's Best Bedding Awards for the Evercool® Cooling Comforter (2023, 2024, 2025), Apartment Therapy's Best List Awards (2023), Health Sleep Awards for the Evercool®+ Cooling Sheet Set (2025), and Oprah Daily's Sleep O-Wards for the Evercool® Cooling Pillow (2025). To learn more, please visit View original content to download multimedia: SOURCE Rest Sign in to access your portfolio
Yahoo
04-06-2025
- Business
- Yahoo
PLT to Present New Sleep Ingredient Study at American Academy of Sleep Medicine Conference
Serezin™ Restorative Sleep + Pain Relief is Clinically Demonstrated to Provide Fast-Acting Nighttime and Daytime Pain Relief, Make Falling Asleep Easier and Promote Waking Up Feeling More Alert and Refreshed MORRISTOWN, N.J., June 4, 2025 /PRNewswire/ -- PLT Health Solutions, Inc. announced that it will be presenting clinical study results for its Serezin™ Restorative Sleep + Pain Relief ingredient at the American Academy of Sleep Medicine Conference being held June 7-11 in Seattle, WA USA. Dawna Salter-Farfan, PhD, RD, PLT's Senior Clinical Research Manager, will be conducting a poster session Wednesday, 6/11/2025, at 10:00 AM during the Clinical Sleep Science and Practice session will cover results of a recent clinical trial on Serezin and will present data specifically on results with women. An abstract entitled An Herbal Supplement Improves Restorative Sleep and Sleep Quality, Elevates Mood, and Increases Total Sleep Time," was published in the May edition of the journal SLEEP. ) According to Dr. Salter-Farfan, these presentations are an effort by PLT to reach a wider audience for Serezin research. "We are excited to present our high-impact research findings at SLEEP 2025. We will be showing data demonstrating Serezin improves sleep quality and quantity, but with a special emphasis on the improvements shown within the female-only cohort of our study. While many of us look to tracking devices to understand our sleep, these data often do not align with our experience. Waking up feeling rested, restored, and refreshed is the defining characteristic of a great night's sleep. By providing relief for nighttime aches and pain, Serezin unlocks the benefits of restorative sleep so that men and women can have better days, every day," she added. SLEEP 2025 is the annual meeting of the Associated Professional Sleep Societies, LLC (APSS), a joint venture of the American Academy of Sleep Medicine (AASM) and the Sleep Research Society (SRS). SLEEP is considered the world's premier clinical and scientific meeting for sleep medicine, sleep and circadian research, and sleep health. The meeting brings together leading experts, innovators, and attendees from across the United States and around the world. New Clinical Study Points to Broad Ranging Benefits A comprehensive 4-week, double-blind, placebo-controlled study was conducted on 60 healthy men and women ages 50-70 years. Subjects self-reported disturbed sleep due to everyday aches and pains. They received either a 300 mg dose of Serezin a day or a placebo. Measurements were conducted at 1, 2 and 4 weeks. Key findings Include: Improved Restorative Sleep Within 1 Week: Subjects taking Serezin woke up feeling more rested and restored within the first week. By four weeks, subjects taking Serezin experienced a 64% greater improvement in restorative sleep than those taking placebo. Reduce Every Day Aches and Pains Within 1 Week: Significant improvements in pain scores started on Day 7 for the Serezin group. By Day 28, subjects taking Serezin experienced a 2.6x greater reduction in nighttime discomfort and a 75% greater reduction in daytime discomfort compared to the placebo. Easier to Fall Asleep and Better Sleep Quality Within 2 Weeks: With statistically significant improvements by Day 14, subjects taking Serezin experienced improvements in getting to sleep that were 85% greater than those taking a placebo and 93% greater improvements in sleep quality than those taking a placebo as assessed by the Leeds Sleep Evaluation Questionnaire. Improvements in Wake-Up Experience Within 2 Weeks: Subjects taking Serezin reported having a significantly easier time waking up in the morning and feeling more alert with better motor control upon waking, as assessed by the Leeds Sleep Evaluation Questionnaire. Serezin Improved Mood Within 2 Weeks: Mood states were evaluated using a validated questionnaire covering six domains: tension, depression, anger, vigor, fatigue, and confusion. Serezin subjects reported improved overall mood starting at Day 14. For the study, subjects reported a 2.2x improvement in overall mood. According to Steve Fink, Vice President, Marketing for PLT, the company has a growing range of solutions for sleep and relaxation in its ingredient portfolio. "Cognitive health is an intense area of interest and innovation at PLT today, with a broad portfolio that addresses Cognitive Performance, Mental Energy, Stress and Mood and Sleep and Relaxation. We have active clinical programs supporting all of these consumer needs," he said. "Serezin is an exciting ingredient in the sleep space because it features a different approach to promoting restorative sleep than many of the ingredients on the market today. We feel that this study can help consumer products companies develop compelling, trustworthy messaging for a new generation of sleep support products," he said. Media Contact: Mark FalconerSciencewerks Voice: 407-412-9705E-mail: 396244@ Company Contact: Steve Fink PLT Health Solutions, Inc. Voice: 973-984-0900 x214E-mail: 396244@ View original content to download multimedia: SOURCE PLT Health Solutions Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20-05-2025
- Automotive
- Yahoo
SLEEP Act would make loud vehicle exhausts illegal in Pennsylvania
(WTAJ) — Loud aftermarket exhausts could be a thing of the past in Pennsylvania if the SLEEP Act were to become law. The SLEEP (Stop Loud and Excessive Exhaust Pollution) Act would ban aftermarket exhausts for all vehicles, including ATVs, that are louder than permitted by law. The act would also make it part of the yearly state vehicle inspection to check decibel levels of exhaust systems. The act, being co-sponsored by House representatives Jared Solomon(D-Philadelphia) and Pat Gallagher(D-Philadelphia), is an attempt to reduce noise pollution and improve the quality of life in Pennsylvania neighborhoods. 'Excessively loud vehicles don't just disrupt our peace and quiet—they can also lower property values, increase air pollution, and burden local police with rising noise complaints and enforcement costs,' the duo wrote in a co-sponsorship memo. In addition to banning loud aftermarket exhausts, the act would also do the following: Apply to vehicles made after 1978, whether the modified equipment was installed in Pennsylvania or another state. Set modern noise testing standards using updated decibel limits and distance-based sound measurements. Require law enforcement training on how to measure vehicle noise accurately and enforce the law. Ensure vehicles with illegal exhaust systems fail inspection. Require PennDOT to hold official vehicle inspection stations accountable if they repeatedly allow non-compliant vehicles to pass. Impose penalties of up to $1,000 in fines, 30 days in jail, or both for published memo does not specify when the act might be introduced into the House committee. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
